Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Eton Pharmaceuticals (ETON) over the last 7 years, with Q1 2025 value amounting to $394000.0.

  • Eton Pharmaceuticals' Cash from Financing Activities rose 20423.28% to $394000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $34.0 million, marking a year-over-year increase of 276818.54%. This contributed to the annual value of $32.6 million for FY2024, which is 350574.71% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $394000.0 for Q1 2025, which was up 20423.28% from $33.6 million recorded in Q4 2024.
  • Over the past 5 years, Eton Pharmaceuticals' Cash from Financing Activities peaked at $33.6 million during Q4 2024, and registered a low of -$385000.0 during Q1 2022.
  • Over the past 5 years, Eton Pharmaceuticals' median Cash from Financing Activities value was -$49000.0 (recorded in 2023), while the average stood at $1.9 million.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Cash from Financing Activities tumbled by 115428.57% in 2023, and later surged by 1151904.76% in 2024.
  • Eton Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $68000.0 in 2021, then skyrocketed by 45.59% to $99000.0 in 2022, then plummeted by 396.97% to -$294000.0 in 2023, then skyrocketed by 11519.05% to $33.6 million in 2024, then crashed by 98.83% to $394000.0 in 2025.
  • Its last three reported values are $394000.0 in Q1 2025, $33.6 million for Q4 2024, and -$385000.0 during Q3 2024.